Cargando…
The impact of the rare disease and Orphan Drug Act in Taiwan
The Rare Disease and Orphan Drug Act (the Act) was enacted in 2000 in Taiwan for the facilitation of the research, development, and accessibility of orphan drugs and special nutritional foods; for the prevention and early diagnosis of rare diseases; and for providing intensive care for patients with...
Autores principales: | Hsiang, Ning-Chun, Huang, Weng-Foung, Gau, Churn-Shiouh, Tsai, Teng-Wen, Chang, Lin-Chau |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taiwan Food and Drug Administration
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9931014/ https://www.ncbi.nlm.nih.gov/pubmed/35649145 http://dx.doi.org/10.38212/2224-6614.3383 |
Ejemplares similares
-
Patient Involvement in the Health Technology Assessment Process in Taiwan
por: Chen, Kuei An, et al.
Publicado: (2022) -
Valuation of the EQ-5D-5L in Taiwan
por: Lin, Hsiang-Wen, et al.
Publicado: (2018) -
Regulatory considerations for generic products of non-biological complex drugs
por: Liu, Yu-Hsuan, et al.
Publicado: (2023) -
Epidemiology, clinical profile and treatment patterns of venous thromboembolism in cancer patients in Taiwan: a population-based study
por: Chew, Tan-Wei, et al.
Publicado: (2015) -
Stem cell therapy on skin: Mechanisms, recent advances and drug reviewing issues
por: Chu, Gong-Yau, et al.
Publicado: (2017)